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Objective: To update evidence for available therapies in the treatment of hip and knee osteoarthritis (OA)
and to examine whether research evidence has changed from 31 January 2006 to 31 January 2009.
Methods: A systematic literature search was undertaken using MEDLINE, EMBASE, CINAHL, AMED,
Science Citation Index and the Cochrane Library. The quality of studies was assessed. Effect sizes (ESs)
and numbers needed to treat were calculated for efﬁcacy. Relative risks, hazard ratios (HRs) or odds
ratios were estimated for side effects. Publication bias and heterogeneity were examined. Sensitivity
analysis was undertaken to compare the evidence pooled in different years and different qualities.
Cumulative meta-analysis was used to examine the stability of evidence.
Results: Sixty-four systematic reviews, 266 randomised controlled trials (RCTs) and 21 new economic
evaluations (EEs) were published between 2006 and 2009. Of 51 treatment modalities, new data on
efﬁcacy have been published for more than half (26/39, 67%) of those for which research evidence was
available in 2006. Among non-pharmacological therapies, ES for pain relief was unchanged for self-
management, education, exercise and acupuncture. However, with new evidence the ES for pain relief
for weight reduction reached statistical signiﬁcance, increasing from 0.13 [95% conﬁdence interval (CI)
0.12, 0.36] in 2006 to 0.20 (95% CI 0.00, 0.39) in 2009. By contrast, the ES for electromagnetic therapy
which was large in 2006 (ES¼ 0.77, 95% CI 0.36, 1.17) was no longer signiﬁcant (ES¼ 0.16, 95% CI 0.08,
0.39). Among pharmacological therapies, the cumulative evidence for the beneﬁts and harms of oral and
topical non-steroidal anti-inﬂammatory drugs, diacerhein and intra-articular (IA) corticosteroid was not
greatly changed. The ES for pain relief with acetaminophen diminished numerically, but not signiﬁcantly,
from 0.21 (0.02, 0.41) to 0.14 (0.05, 0.22) and was no longer signiﬁcant when analysis was restricted to
high quality trials (ES¼ 0.10, 95% CI 0.0, 0.23). New evidence for increased risks of hospitalisation due
to perforation, peptic ulceration and bleeding with acetaminophen >3 g/day have been published
(HR¼ 1.20, 95% CI 1.03, 1.40). ES for pain relief from IA hyaluronic acid, glucosamine sulphate, chon-
droitin sulphate and avocado soybean unsponiﬁables also diminished and there was greater heteroge-
neity of outcomes and more evidence of publication bias. Among surgical treatments further negative
RCTs of lavage/debridement were published and the pooled results demonstrated that beneﬁts from this
modality of therapy were no greater than those obtained from placebo.
Conclusion: Publication of a large amount of new research evidence has resulted in changes in the
calculated risk–beneﬁt ratio for some treatments for OA. Regular updating of research evidence can help
to guide best clinical practice.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.to: Weiya Zhang, Academic Rheumatology, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK.
. Zhang).
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Osteoarthritis (OA) of the hip and knee are major causes of pain
and locomotor disability worldwide. The OA Research Society Inter-
national (OARSI) has recently published global, evidence-based,
consensus recommendations for the treatment of OA of the hip and
knee1 following a critical appraisal of existing guidelines and
a systematic review (SR) of the evidence for relevant therapies from
2002until January20062. Aconsiderablenumberofnewstudieshave
been published in the past 3 years. As an aid to assessing whether
current OARSI recommendations should be modiﬁed in the light of
this recent evidence, this paper updates the published evidence for
available therapies from 31 January 2006 to 31 January 2009.
Methods
Systematic literature search
A systematic literature search was undertaken for SRs or meta-
analyses (MAs), randomised controlled trials (RCTs), observational
studies and economic evaluations (EEs) for the management of hip
and/or knee OA published in any language between January 2006
and January 2009. Search strategies and electronic databases used
previously were repeated2.
Study selection
To update research evidence, studies for the treatment of hip and
knee published between 31 January 2006 and 31 January 2009 were
included. SRs/MAs were selected if available and supplemented by
RCTs published subsequently. RCTs were selected if there were no
published SRs/MAs. If there was more than one SR for the same
treatment, the latest SR containing most studies and having the best
quality characteristics was used and others were cross-checked to
ensure that all RCTs were included in the database. Information
concerning side effects was obtained from both RCTs and observa-
tional studies.While theefﬁcacyofeach therapeutic interventionwas
assessed separately for hip and knee OA, side effects were evaluated
for each intervention regardless of the target joint. For determination
of cost-effectiveness, only cost-utility analyses were included2.
To examine change between 2006 and 2009, primary studies for
the treatment of hip and knee OA were identiﬁed through pub-
lished SRs/MAs. New primary studies published after the SRs/MAs
were added. Multiple SRs/MAs were cross-checked to ensure that
all published primary studies were included. Authors were con-
tacted to validate data if necessary.
Quality and content assessment
Data were extracted using six customised extraction forms accord-
ing to study design (SR, RCT, cohort, case–control, cross-sectional
studies and EE). On each form for each study demographic data,
qualityscoresandoutcomeswererecorded.ThequalityofSRs/MAswas
assessedusing theOxmanandGuyatt checklist3 and thequalityof RCTs
was evaluated using the Jadad method4. All quality scores were con-
verted into percentages of the maximum score attainable. For each
modality of treatment the studies with the highest level of evidence
(LoE)5, and thehighestqualityof study (QoS)wereused torepresent the
best evidence for efﬁcacy (Table I). Quality assessments were not
undertaken for other types of study design, such as cohort or case–
control studies. For each EE, the study perspective, comparator, time
horizon, discounting, modelling and uncertainty were evaluated.
Data analyses
Effect sizes (ESs) and number needed to treat (NNT) were used
for efﬁcacy, whereas relative risks (RRs), hazard ratios (HRs) andodds ratios (ORs) were estimated for side effects. Whenever
possible, these outcome measures were extracted/calculated for
each study. Publication bias was examined using funnel plots and
an Egger’s test6. Heterogeneity was examined using Forest plots
and Q tests, and the degree of heterogeneity was calculated and
presented as the I2 – the percentage of the variance across studies
that cannot be attributed to chance7. Reasons for heterogeneity
were explored using sub-group analysis, and overall pooling of data
was undertaken as appropriate. Sensitivity analyses were under-
taken to examine changes from 2006 and 2009 and differences
between analyses obtained from pooling all studies and from
pooling only higher quality studies with a Jadad score of 5.
Cumulative MAwas used to assess changes in treatment ES year by
year in order to document any signiﬁcant trends associated with
accruing evidence. Cost-effectiveness was estimated by calculation
of cost per quality-adjusted life year (QALY) gained2. A glossary of
terms and abbreviations is listed in Appendix I.
Results
SR of the scientiﬁc literature published between January 2006
and January 2009 identiﬁed 64 SRs, 266 RCTs and 21 EEs, which
met the inclusion criteria. Of the 51 modalities of treatment
addressed in the OARSI recommendations, 35 have now been
systematically reviewed with 16 new or updated SRs in the last 3
years.
The best available evidence for ES with 95% conﬁdence intervals
(CIs) for relief of pain and stiffness and improvement in function for
non-pharmacological, pharmacological and surgical treatments for
OA of the hip and knee in January 2009 is summarised in Table I
together with the LoE and the quality of studies on which these
numbers are based. Table I also shows the NNT for each therapy
where these can be calculated.
Non-pharmacological treatments
Self-management, education and information
Self-management, education and provision of information
about OA and its treatment are widely promulgated as core
recommendations for the treatment of OA hip and knee in recent
guidelines from National Institute of Health and Clinical Excellence
(NICE)8 and the American Academy of Orthopaedic Surgeons
(AAOS)9 as well as in the OARSI guidelines1 and in many previously
published guidelines2.
A new RCT undertaken in a UK primary care setting compared
outcomes following a self-management course including an
educational booklet, with administration of the educational
booklet alone10. The results showed no signiﬁcant differences
between the two groups for reduction in Western Ontario and
McMaster Universities OA index (WOMAC) scores for pain and
stiffness, or improvement in physical function at 4 months and 12
months. ESs were 0.02 (95% CI 0.11, 0.16) for reduction in pain,
0.01 (0.12, 0.15) for reduction in stiffness and 0.06 (0.08, 0.20)
for functional improvement at 4 months. When combined with the
results of trials included in the previous MA11, the overall ES for
reduction in pain and improvement in function remained
extremely small (0.06, 95% CI 0.02, 0.10) but statistically signiﬁcant
(Tables I and II).
In another RCT performed in a primary care setting in France,
standardised consultations which included education about OA,
advice about physical exercise and weight reduction were
compared with usual care12. At 4 months the standardised inter-
vention was followed by an average weight reduction of 1.11 (SD
2.49) kg, compared with only 0.37 kg (SD 2.39) (P¼ 0.007) in the
group receiving usual care. However, these differences in weight
Table I
Best evidence for efﬁcacy for various modalities of therapy for hip and knee OA available 31 January 2009
Modality Joint QoS
(%)
LoE Best evidence until 31 January 2009
ESpain (95% CI) ESfunction (95% CI) ESstiffness (95% CI) NNT (95% CI)
Non-pharmacological
Self-management Both 100 Ia 0.06 (0.02, 0.10)10,11,* 0.06 (0.02, 0.10)10,11,* 0.01 (0.12, 0.15)10,*
Telephone Both 100 Ia 0.12 (0.00, 0.24)154 0.07 (0.00, 0.15)154
Education Both 100 Ia 0.06 (0.03, 0.10)11,12,* 0.06 (0.02, 0.10)11
Strengthening Knee 100 Ia 0.32 (0.23, 0.42)20 0.32 (0.23, 0.41)20
Hip* 100* Ia* 0.38 (0.08, 0.68)15,*
Aerobic Knee 100 Ia 0.52 (0.34, 0.70)20 0.46 (0.25, 0.67)20
Water-based exercise Both 100* Ia* 0.19 (0.04, 0.35)13,* 0.26 (0.11, 0.42)13,* 0.17 (0.05, 0.39)155
Balneotherapy Knee 75 Ia NS156
Spa/sauna Both 75 Ib 0.46 (0.17, 0.75)157 NS
Weight reduction Knee 100* Ia* 0.20 (0.00, 0.39)21,* 0.23 (0.04, 0.42)21,* 0.36 (0.08, 0.80)158 3 (2, 9)158
TENS Both 75 Ia 2 (1, 5)159
Laser Both 100 Ia 4 (2,17)160
Ultrasound Both 50 Ia 0.06 (0.39, 0.52)161
Radiotherapy Both 50 IIb Similar effects between OA
and RA from an MA of
uncontrolled trial162
Heat/ice Knee 75 Ia 0.69 (0.07, 1.45)163 1.03 (0.44, 1.62)163 for
quads strength; 1.13
(0.54, 1.73)163 for ﬂexion
0.83(0.03, 1.69)163 for
swelling
Massage Knee 40 Ib 0.10 (0.23, 0.43)164
Acupuncture Knee 100* Ia* 0.35 (0.15, 0.55)23,* 0.35 (0.14, 0.56)23,* 0.41 (0.13, 0.69)30 4 (3, 9)30
Insoles Knee 100 Ia No different between type
of insoles, no placebo/usual
care comparisons165
Joint protection (braces) Knee 100 Ia More beneﬁts with a knee
brace than a neoprene
sleeve165
Electrotherapy/EMG Knee 100* Ia* 0.16 (0.08, 0.39)31,* 0.33 (0.07, 0.59)31,*
Pharmacological
Acetaminophen Both 100 Ia 0.14 (0.05, 0.23)32,34* 0.09 (0.03, 0.22)34,166,167,* 0.16 (0.05, 0.37)166,168,* 3 (2, 52)34–36,*
NSAIDs Both 100 Ia 0.29 (0.22, 0.35)44,*
NSAIDsþ PPIs OA/
RA
100 Ia
NSAIDsþH2-blockers OA/
RA
100 Ia
NSAIDsþmisoprostol OA/
RA
100 Ia
Cox-2 inhibitors Both 100 Ia 0.44 (0.33, 0.55)169
(exc Deek’s for OA/RA)
Topical NSAIDs Knee 100 Ia 0.44 (0.27, 0.62)48–51,* 0.36 (0.24, 0.48)48 0.49 (0.17, 0.80)48 3 (2, 4)48
Topical capsaicin Knee 75 Ia 4 (3, 5)170
Opioids Any* 100* Ia* 0.78 (0.59, 0.98)58,* 0.31 (0.24, 0.39)58,*
IA corticosteroid Knee 100 Ia 0.58 (0.34, 0.75)44,* 0.20 (0.14, 0.53)61,* 0.25 (0.23, 0.74)61,* 5 (3, 38)61,*
IAHA Knee 100 Ia 0.60 (0.37, 0.83)65,* 0.61 (0.35, 0.87)65,* 0.54 (0.17, 1.26)65,* 7 (3, 119)65,*
GS Both 100 Ia 0.58 (0.30, 0.87)34,80,82,* 0.07 (0.08, 0.21)84 0.06 (0.11, 0.23)84 5 (4, 7)96
GH* Knee* – Ib* 0.02 (0.15, 0.11)81,171,172,*
CS Knee 100 Ia 0.75 (0.50, 1.01)95,* 5 (4, 7)96
Diacerhein Both – Ib 0.24 (0.08, 0.39)112–115,119,120,* 0.14 (0.03, 0.25)112–115,119,120,*
ASU Both* 100* Ia* 0.38 (0.01, 0.76)99,* 0.45 (0.21, 0.70)99,* 6 (4, 21)99,*
Rosehip* Both* 100* Ia* 0.37 (0.13, 0.60)108,* 6 (4, 13)108,*
SAM-e Knee 100 Ia 0.22 (0.25, 0.69)106 0.31 (0.10, 0.52)106
Surgical
Lavage/debridement* Knee* – Ib* 0.21 (0.12,
0.54)130,132,133,135,173,*
0.11 (0.11,
0.33)130,132,133,135,173,*
0.05 (0.34, 0.44)130,132,173,*
Patellar resurfacing Knee 100 Ib 9 (5, 25)174
Osteotomy Knee 100* Ia* Head to head comparisons, no placebo or conservative therapy controlled trials. HTO improves pain and
function137,*
Unicompartment knee
arthroplasty*
Knee* 75* SR
cohort*
Similar function improvement as TKR or HTO, but less complications and revision than HTO139,*
TJR Both 100 III TJR is effective to improve QoL, more beneﬁcial for hip OA from an SR of cohort studies175
Abbreviations: TENS: trans cutaneous electrical nerve stimulation; ES¼ 0.2 is considered small, ES¼ 0.5 is moderate, and ES> 0.8 is large; NNT for symptom relief, unless
otherwise speciﬁed; NS: not signiﬁcant; TJR: total joint replacement.
Ia: MA of RCTs; Ib: RCT; IIa controlled studywithout randomisation; IIb: quasi-experimental study (e.g., uncontrolled trial, one arm dose–response trial, etc.); III: observational
studies (e.g., case–control, cohort, cross-sectional studies); IV: expert opinion.
QoS was assessed using validated scales, e.g., the Oxman and Guyatt scale for SR and the Jadad’s scale for clinical trials. The percentage score was calculated for each study. The
best available evidence was presented, i.e., SR with the highest quality, RCT with highest quality followed by uncontrolled or quasi experiment, cohort and case–control study.
* Updated since 20062.
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the two groups (ES¼ 0.19, 95% CI0.02, 0.41), and this did not alter
the overall estimate of the effect of educational intervention on
symptomatic outcomes in OA signiﬁcantly (Table II).
Exercise
Seven new SRs of exercise therapy in OA hip and knee have been
undertaken in the past 3 years13–19. In addition to conﬁrming the
conclusion from the earlier MA that both strengthening and aerobic
exercise are associated with relief of pain in knee OA20, one SR
found that exercise, particularly strengthening exercise, was also
associated with reduction in pain in hip OA (ES¼ 0.38, 95% CI 0.08,
0.68)15, and another showed that water-based exercise resulted in
relief of pain (ES¼ 0.19, 95% CI 0.04, 0.35), and improvement in
function (0.26, 95% CI 0.11, 0.42) in both knee and hip OA13 (Table I).
The reported costs per QALY were very variable depending on the
type of exercise, the comparator used, the country where the study
was undertaken and the perspective from which the EE was
undertaken (Table V).Within study direct comparisons suggest that
class-based exercise may be more economically efﬁcient than
home-based exercise, indirect comparisons between studies
suggest that water-based exercise may not necessarily be more
cost-effective than land based exercise (Table V).
Weight reduction
Two relevant SRs have been published since 2006. One reviewed
studies of physical therapy interventions which included weight
reduction16 while the other focussed on studies speciﬁcally
designed to look at outcomes in patients with knee OA as a result of
therapeutic weight reduction21. There are now four published RCTs
which have examined symptomatic outcomes following weight
reduction. The pooled ESs (95% CI) for improvement in pain and
physical function were 0.20 (0.00, 0.39) and 0.23 (0.04, 0.42)
following an average reduction in weight of 6.1 kg (4.7, 7.6)21. As
indicated in the OARSI recommendations1 this SR21 provided
evidence for small improvements in pain and physical function inTable II
Comparison of ESs and LoE for pain relief with different modalities of therapy in
2006 and 2009
31 January 2006
ES (95% CI), LoE
31 January 2009
ES (95% CI), LoE
Self-management 0.06 (0.02, 0.10), Ia 0.06 (0.02, 0.10), Ia
Education/information 0.06 (0.02, 0.10), Ia 0.06 (0.03, 0.10), Ia
Exercise for knee OA
Strengthening 0.32 (0.23, 0.42), Ia 0.32 (0.23, 0.42), Ia
Aerobic 0.52 (0.34, 0.70), Ia 0.52 (0.34, 0.70), Ia
Exercise for hip OA NA 0.38 (0.08, 0.68), Ia
Exercise in water for knee & hip
OA
0.25 (0.02, 0.47), Ib 0.19 (0.04, 0.35), Ia
Weight reduction 0.13 (0.12, 0.36), Ib 0.20 (0.00, 0.39), Ia
Acupuncture 0.51 (0.23, 0.79), Ib 0.35 (0.15, 0.55), Ia
Electromagnetic therapy 0.77 (0.36, 1.17), Ia 0.16 (0.08, 0.39), Ia
Acetaminophen 0.21 (0.02, 0.41), Ia 0.14 (0.05, 0.22), Ia
NSAIDs 0.32 (0.24, 0.39), Ia 0.29 (0.22, 0.35), Ia
Topical NSAIDs 0.41 (0.22, 0.59), Ia 0.44 (0.27, 0.62), Ia
Opioids NA 0.78 (0.59, 0.98), Ia
IA corticosteroid 0.72 (0.42, 1.02), Ia 0.58 (0.34, 0.75), Ia
IAHA 0.32 (0.17, 0.47), Ia 0.60 (0.37, 0.83), Ia
GS 0.61 (0.28, 0.95), Ia 0.58 (0.30, 0.87), Ia
GH NA 0.02 (0.15, 0.11), Ib
CS 0.52 (0.37, 0.67), Ia 0.75 (0.50, 1.01), Ia
Diacerein 0.22 (0.01, 0.42), Ib 0.24 (0.08, 0.39), Ib
ASU NA 0.38 (0.01, 0.76), Ia
Rosehip NA 0.37 (0.13, 0.60), Ia
Lavage/debridement 0.09 (0.27, 0.44), Ib 0.21 (0.12, 0.54), Ib
NA: not available.
The sources of the data for each modality of therapy are shown in Table I and Ref. 2.patients with knee OA following weight reduction which was not
available in 2006. However, the recommendation that patients with
hip OA should be encouraged to lose weight and maintain their
weight at a lower level is still only based on expert opinion
unsupported by research evidence (LoE IV).
Acupuncture
Nine SRs of the use of acupuncture for the treatment of OA
published between 2006 and 200916,22–29 have conﬁrmed that this
non-pharmacological modality of treatment does have some efﬁ-
cacy for relief of pain. The latest MA included results from 11
RCTs23. Acupuncture was compared with sham acupuncture, usual
care or waiting list controls. Overall, acupuncture was superior to
controls with a pooled ES of 0.58 (0.38, 0.78) for pain relief.
However, the ES was lower in blinded trials with sham acupuncture
controls (ES¼ 0.35, 95% CI 0.15, 0.55). The ES for relief of pain also
diminished with time and was 0.13 (0.01, 0.24) 6 months after
treatment23. Similar ﬁndings were observed for improvement in
function (Table I). The cost per QALYof acupuncture in comparisons
with sham acupuncture was about $30,51930 (Table V).
Electromagnetic therapy
Treatment of OA knee or hip with electromagnetic therapy was
not recommended in the OARSI guidelines1 despite evidence from
a 2002 Cochrane review suggesting that it might be associated with
relatively large improvements in pain in patients with knee OA
(ES¼ 0.77, 95% CI 0.36, 1.17). A subsequent SR published in 200631,
immediately after the closing date of the literature search available
to the OARSI treatment guidelines development group, included
ﬁve placebo-controlled RCTs of pulsed electromagnetic ﬁeld
therapy published between 1996 and 2005. The cumulative data
showed that improvement in function was small (ES¼ 0.33, 95% CI
0.07, 0.59), and there was no signiﬁcant efﬁcacy for reduction in
pain (ES¼ 0.16, 95% CI 0.08, 0.39)31; very different from the
results in the earlier review2.Pharmacological treatments
Acetaminophen (paracetamol)
The Cochrane review of acetaminophen was updated in 200632.
The update, which included seven placebo-controlled RCTs,
demonstrated a statistically non-signiﬁcant reduction in the ES for
pain reduction (ES¼ 0.13, 95% CI 0.04, 0.22), compared with that
previously estimated in an MA of trials in 2004 (ES¼ 0.21, 95% CI
0.02, 0.41)33. Acetaminophen was subsequently shown to have no
signiﬁcant effect in reducing pain in knee OA in the Glucosamine
Unum In Die (once a day) Efﬁcacy (GUIDE) RCT (ES¼ 0.16, 95% CI
0.11, 0.43) which was published in 2007 after completion of the
Cochrane update34. A funnel plot of the ﬁve trials that measured
pain outcomes does not suggest signiﬁcant publication bias (Fig. 1).
The trials were homogenous with a pooled ES for pain relief of 0.14
(0.05, 0.23) (Fig. 2). Cumulative MA suggests that though the ES for
pain relief is small, it is now stable and unlikely to diminish further,
given that there is homogeneity within the published trials and
nothing to suggest publication bias (Fig. 3). However, currently
available evidence suggests that acetaminophen has no signiﬁcant
effect on stiffness (ES¼ 0.16, 95% CI 0.05, 0.37) or physical func-
tion (ES¼ 0.09, 95% CI 0.03, 0.22) in patients with symptomatic
knee OA (Table I).
The NNT to obtain relief of pain was calculated from the results
of one cross-over and the two parallel design trials34–36. Although
the pooled NNT was only 3 (95% CI 2, 52), there was signiﬁcant
heterogeneity and the NNT ranged from 2 to 8 in the three RCTs.
This wide range was largely attributable to the exceptionally small
Test for publication bias: 
Egger: bias = 0.055 (95% CI = -2.5 to 2.63)  P = 0.9556 
Bias assessment 
-0.5 0.0 0.5 1.0
0.30
0.25
0.20
0.15
0.10
0.05
Effect size
Standard error
Fig. 1. Funnel plot of trials of analgesic efﬁcacy of acetaminophen in OA.
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Pincus a 2004
0.11 (0.01, 0.22)
Miceli-Ricard 2004 0.11 (-0.01, 0.23)
Golden 2004 0.16 (-0.05, 0.37)
Case 2003 -0.003 (-0.55, 0.49)
Cumulative effect size (95% confidence) 
Fig. 3. Cumulative MA of RCTs of analgesic efﬁcacy of acetaminophen in OA.
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trial the NNT was 7 (4, 23).
More evidence has accumulated to suggest that acetaminophen
may have upper gastrointestinal (GI) side effects. A population-
based cohort study (n¼ 644,183) showed that treatment with
high dose (>3 g/day) acetaminophenwas associated with a greater
risk of hospitalisation as a result of GI perforation, ulceration or
bleedings (PUBs) than treatment with low dose acetaminophen
(3 g/day) with an HR of 1.20 (1.03, 1.40)37. There is also some
evidence for mild loss of renal function in women following long-
term consumption of such doses (OR¼ 2.04, 95% CI 1.28, 3.24) for
decline in glomerular ﬁltration rate (GFR)> 30 ml/min38 and
evidence from prospective cohort studies for increases in incident
hypertension in women taking> 500 mg acetaminophen daily39Test for heterogeneity: 
Cochran Q = 2.10 (df = 5)  P = 0.8
I² (inconsistency) = 0% (95% CI = 
Summary meta-a
-0.60 -0.35 -0.10
combined
Herrero-Beaumont 2007
Pincus b 2004
Pincus a 2004
Miceli-Ricard 2004
Golden 2004
Case 2003
Effect size (95%
Fig. 2. Forest plot of RCTs for analgesicand in men taking daily acetaminophen when compared with
non-users (RR¼ 1.34, 95% CI 1.00, 1.79)40.
Acetaminophen, in doses of up to 4 g/day, is currently a core
recommendation for use as an analgesic in the OARSI guidelines1,
the recently published NICE8 and AAOS9 guidelines as well as other
guidelines for the management of hip or knee OA available in
20062. European League Against Rheumatism (EULAR) recom-
mendations for the management of hip41 and knee42 OA suggested
that doses of up to 4 g/day should be the oral analgesic of ﬁrst
choice for mild-moderate pain because of its relative safety and
efﬁcacy and, if successful, should be used as the preferred long-
term oral analgesic. The strength of recommendation (SOR) for the
use of acetaminophen in doses up to 4 g/day for the initial treat-
ment of mild to moderate pain in patients with knee or hip OA in
the OARSI recommendations was high (SOR¼ 92, 95% CI 88, 99)
despite uncertainties about the long-term efﬁcacy and safety of
such doses of the drug at the time of publication1. Because of
additional concerns about acetaminophen’s narrow therapeutic
margin for hepatotoxicity, an advisory committee of the US Food353 
0% to 61%) 
nalysis plot [fixed effects]
0.15 0.40 0.65
0.14 (0.05, 0.23)
0.16 (-0.11, 0.43)
0.23 (0.03, 0.44)
0.13 (-0.09, 0.34)
0.08 (-0.07, 0.22)
0.20 (-0.03, 0.43)
-0.03 (-0.55, 0.49)
 confidence interval)
efﬁcacy of acetaminophen in OA.
Table III
Relationship between ES for pain relief and quality of randomized controlled trial
All trials
ES (95% CI)
High quality trials (Jaded¼ 5),
ES (95% CI)
Acupuncture 0.35 (0.15, 0.55) 0.22 (0.01, 0.44)
Acetaminophen 0.14 (0.05, 0.23) 0.10 (0.03, 0.23)
NSAIDs 0.29 (0.22, 0.35) 0.39 (0.24, 0.55)
Topical NSAIDs 0.44 (0.27, 0.62) 0.42 (0.19, 0.65)
IAHA 0.60 (0.37, 0.83) 0.22 (0.11, 0.54)
GS 0.58 (0.30, 0.87) 0.29 (0.003, 0.57)
CS 0.75 (0.50, 1.01) 0.005 (0.11, 0.12)
ASU 0.38 (0.01, 0.76) 0.22 (0.06, 0.51)
Lavage/debridement 0.21 (0.12, 0.54) 0.11 (0.30, 0.08)
The source of the data for each treatment is shown in Table I.
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maximum adult daily dose of acetaminophen should be less than
4 g/day and that the acetaminophen content in single doses of over
the counter (OTC) analgesic preparations should be limited to
650 mg43.
Non-steroidal anti-inﬂammatory drugs (NSAIDs)
A new SR of therapy with oral NSAIDs published in 200744
included data from 27 placebo-controlled RCTs (n¼ 14,523). The
pooled, updated, ES for pain relief was little reduced (ES¼ 0.29, 95%
CI 0.22, 0.35) (Table II). Although this is in the small to moderate
range it is two-fold greater than the ES for relief of pain with
acetaminophen (ES¼ 0.14, 95% CI 0.05, 0.23)32 (Tables I and II).
Evidence that NSAIDs are superior to acetaminophen for the
relief of pain is supported by an SR of head to head comparisons
between NSAIDs and acetaminophen (ES¼ 0.20, 95% CI 0.10,
0.30)33. The clinical response rate was higher (RR¼ 1.24, 95% CI
0.10, 1.41) and the number of patients preferring NSAIDs to acet-
aminophenwas consistently greater (RR¼ 2.46, 95% CI 1.50, 4.12)33.
The incidence of serious GI side effects associated with the use
of oral NSAIDs was also assessed in the large population-based
cohort study of elderly patients in Canada37. The HR for GI hos-
pitalisation from PUBs was higher in patients receiving oral
NSAIDs (1.63, 95% CI 1.44, 1.85) than in patients being treated with
high dose acetaminophen (1.20, 95% CI 1.03, 1.40). However, the
HR was markedly greater (2.55, 95% CI 1.98, 3.28) in patients
treated with NSAIDs plus high dose acetaminophen37. Using a Cox
regression model with time-dependent exposure to determine the
association between drug exposure and GI hospitalisation these
investigators also conﬁrm that the HR for GI hospitalisation in
patients receiving non-selective NSAIDs was twice as high as that
in patients given the cyclooxygenase (Cox)-2 selective agent cel-
ecoxib (2.18, 95% CI 1.82, 2.61), or non-selective NSAIDs together
with a proton pump inhibitor (PPI) (2.21, 95% CI 1.51, 3.24)37.
A recent RCT showed that while treatment with celecoxib alone
was associated with a 9% risk of recurrent GI bleeding in very high
risk patients with previous history of a GI bleed, this could be
abolished by co-prescription of a PPI with celecoxib45. This was
supported by the data from the population-based retrospective
cohort study, in which co-prescription of a PPI was associated with
a reduction in hospital admissions for GI bleeds of about 30% in
people over the age of 75 years when compared with treatment
with celecoxib without additional gastroprotection (HR¼ 0.69,
95% CI 0.52, 0.93)46. A recent cost-utility analysis (CUA) suggested
that co-prescription of a PPI with both traditional NSAIDs and Cox-
2 selective agents is cost-effective at 3 months in a UK National
Health Service setting47.
Topical NSAIDs
Topical NSAIDs were recommended therapies for the treatment
of symptomatic knee OA in 7/9 of the existing guidelines reviewed
in 20062 and are recommended in the more recent guidelines from
NICE8 and OARSI1 as alternative or adjunctive therapy. A total of 14
placebo-controlled RCTs have been reported, including 11 that were
included in a 2004 MA48 and three that have been subsequently
published49–51. The pooled ES for relief of pain is now 0.44 (95% CI
0.27, 0.62) but there is heterogeneity of efﬁcacy between products
(I2¼ 69%) as well as signiﬁcant asymmetry in a funnel plot, also
noted in an earlier MA48, suggesting publication bias with under
reporting of negative studies leading to possible overestimation of
the efﬁcacy of topical NSAIDs. The earlier studies which suggested
that topical NSAIDs were as effective as, and possibly safer than,
oral NSAIDs52–54 are largely supported by a recent RCT and pref-
erence study comparing topical ibuprofen and oral ibuprofen for
the treatment of chronic knee pain in elderly subjects in a primarycare setting55. However, cost-utility analyses showed that in the
second year of the 2-year RCT, oral ibuprofen was more effective,
but more costly, than topical ibuprofen. The cost per QALY of oral
ibuprofen compared with topical ibuprofen was £27,130 (equiva-
lent to US $49,448 in 2009)56,57 (Table V).
Opioids
As previously reported in the OARSI guidelines1, an MA of 18
placebo-controlled RCTs of opioid analgesics in 3244 patients with
OA published in 2007, which was not available at the time of the
2006 OARSI review, showed a moderate to large ES for reduction
in pain intensity (0.78, 95% CI 0.59, 0.98) and a small to moderate
ES for improvement in physical function (0.31, 95% CI 0.24, 0.39)58
(Table I). There was, however, substantial heterogeneity in
outcomes between studies which did not appear to be related to
the particular opioid used or to the methodological quality of the
RCTs58. Beneﬁts associated with the use of opioids were limited by
frequent side effects, including nausea (30%), constipation (23%),
dizziness (20%), somnolence (18%) and vomiting (13%)58 (Table
IV). Overall, 25% of patients treated with opioids withdrew from
studies compared with 7% of placebo-treated patients with
a number needed to harm (NNH) of 5. The withdrawal rate was
higher (31%, NNH 4) for strong opioids (oxymorphone, oxycodone,
oxytrex, fentanyl, morphine sulphate) than for the weaker opioids
(tramadol, tramadol/paracetamol, codeine and propoxyphene)
(19%, NNH 9)58. An MA of six placebo-controlled RCTs of opioids
(tramadol, morphine, codeine, oxycodone and oxymorphone) in
1057 patients with knee OA associated with moderately severe
pain (mean of 64.3 mm on a visual analogue pain scale) only
showed a small improvement in pain (10.5 mm, 95% CI 7.4, 13.7)
compared with placebo which was maximal at 2–4 weeks44. This
was only just above the minimal perceptible threshold59 and the
authors also suggested that even this apparent efﬁcacy of opioids
may be inﬂated because of the high withdrawal rates and
a tendency to report ‘best case’ scenarios when undertaking
intention to treat (ITT) analyses44. Another MA of 41 RCTs for
chronic non-cancer pain involving 6019 patients, 80% of whom
had OA, back pain or rheumatoid arthritis, found that only strong
opioids were signiﬁcantly more effective than acetaminophen or
NSAIDs (ES¼ 0.34, 95% CI 0.01, 0.67)60.
Intra-articular (IA) corticosteroids
Two SRs have been published since 200644,61. The pooled ES for
pain reduction, irrespective of the number of doses administered or
the time after injection was 0.58 (0.34, 0.82), corresponding to an
NNT of 5 (3, 38)44. The ES for relief of pain following single injec-
tions of IA corticosteroid was relatively large; 0.72 (0.42, 1.01) 1
week following injection, with an NNT of only 3 (2, 5)61. However,
this fell to 0.28 (0.17, 0.73) after 4 weeks and 0.21 (0.17, 0.59)
Table IV
Side effects associated with pharmacological therapies
Intervention* Adverse events RR/OR (95% CI) Evidence (references)
Acetaminophen (paracetamol) GI discomfort 0.80 (0.27, 2.37) Meta-RCTs33
GI perforation/bleed 3.60 (2.60, 5.10) CC176
GI bleeding 1.20 (0.80, 1.70) Meta-CCs177
GI hospitalisationy 1.20 (1.03, 1.40)y CS37,y
Renal failure 0.83 (0.50, 1.39) CS178
Renal failure 2.50 (1.70, 3.60) CC179
NSAIDs GI perforation/ulcer/bleed 5.36 (1.79, 16.10) Meta-RCTs180
GI perforation/ulcer/bleed 2.70 (2.10, 3.50) Meta-CSs180
GI perforation/ulcer/bleed 3.00 (2.50, 3.70) Meta-CCs180
GI hospitalisationy 1.63 (1.44, 1.85)y CS37,y
Myocardial infarction 1.09 (1.02, 1.15) Meta-CSs181
Topical NSAIDs GI events 0.81 (0.43, 1.56) Meta-RCTs48
GI bleed/perforation 1.45 (0.84, 2.50) Case–control53
NSAIDþH2-blocker vs NSAID Serious GI complications 0.33 (0.01, 8.14) Meta-RCTs182
Symptomatic ulcers 1.46 (0.06, 35.53) Meta-RCTs182
Serious CV or renal events 0.53 (0.08, 3.46) Meta-RCTs182
NSAIDþ PPI vs NSAID Serious GI complications 0.46 (0.07, 2.92) Meta-RCTs182
Symptomatic ulcers 0.09 (0.02, 0.47) Meta-RCTs182
Serious CV or renal events 0.78 (0.10, 6.26) Meta-RCTs182
Cox-2 inhibitorsþ PPI vs Cox-2 inhibitorsy Recurrent ulcer bleedingy 8.9% vs 0%y RCT45,y
GI hospitalisationy 0.69 (0.52, 0.93)y CS46,y
NSAIDþmisoprostol vs NSAID Serous GI complications 0.57 (0.36, 0.91) Meta-RCTs182
Symptomatic ulcers 0.36 (0.20, 0.67) Meta-RCTs182
Serious CV or renal events 1.78 (0.26, 12.07) Meta-RCTs182
Diarrhea 1.81 (1.52, 2.61) Meta-RCTs183
Cox-2 inhibitors
Coxibs vs NSAID Serious GI complications 0.55 (0.38, 0.80) Meta-RCTs182
Symptomatic ulcers 0.49 (0.38, 0.62) Meta-RCTs182
Serious CV or renal events 1.19 (0.80, 1.75) Meta-RCTs182
Celecoxib Myocardial infarction 2.26 (1.00, 5.10) Meta-RCTs184
Myocardial infarction 0.97 (0.86, 1.08) Meta-CSs/CCs181
Rofecoxib Myocardial infarction 2.24 (1.24, 4.02) Meta-RCTs149
Myocardial infarction 1.27 (1.12, 1.44) Meta-CSs/CCs181
Valdecoxib CV events 2.30 (1.10, 4.70) Meta-RCTs185
Opioids Any 1.40 (1.30, 1.60) Meta-RCTs186
Constipationy 4.08 (3.30, 5.05)y Meta-RCTs58,y
Nauseay 3.15 (2.68, 3.72)y Meta-RCTs58,y
Vomitingy 5.99 (4.20, 8.54)y Meta-RCTs58,y
Dizzinessy 3.74 (3.00, 4.66)y Meta-RCTs58,y
Somnolencey 4.78 (3.65, 6.26) Meta-RCTs58,y
Glucosamine Any 0.97 (0.88, 1.08) Meta-RCTs84
Chondroitin sulphate Any 0.99 (0.76, 1.31) Meta-RCTs95,y
Diacerhein Diarrhoea 3.51 (2.55, 4.83)y Meta-RCTs112–115,119,120,y
IAHA Local adverse eventsy 1.49 (1.21, 1.83)y Meta-RCTs65,y
IA high molecular HA (Hylan) Flares of pain and swellingy 2.04 (1.18, 3.53)y Meta-RCTs74,y
CC: case–control study; CS: cohort study.
H2-blockers: histamine type 2 receptor antagonists; CV: cardiovascular.
* Compared with placebo/non-exposure unless otherwise stated.
y Updated since 20062.
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repeated at frequent intervals to maintain efﬁcacy, a long-term trial
of IA corticosteroid injections every 3 months for 2 years showed
that while therewas efﬁcacy for relief of pain after 1 year (ES¼ 0.67,
95% CI 0.18,1.17), this was not demonstrable after 2 years (ES¼ 0.25,
95% CI 0.23, 0.74)61. IA steroid injections had no signiﬁcant effecton physical function (ES¼ 0.20, 95% CI 0.14, 0.53) or stiffness
(ES¼ 0.25, 95% CI 0.23, 0.74)61.
IA hyaluronic acid (IAHA)
No less than 17 SRs and MAs have been undertaken to assess
the therapeutic effects of IAHA in OA, and the majority of these
Table V
Cost per QALY in 2009
Intervention Comparator OA Perspective* Time
horizon
Discounting Year
published
Country Cost per QALY
Original Converted ($)y
Educationþ class-based
exercise
Usual care Hip/knee Societal 65 weeks No 2007 Netherlands 51,385
euros
92,081187
Class-based exercise Home-based
exercise
Knee NHS 1 year No 2004 UK £238 503 (cost saving)188
Water-based exercise Usual care Hip/knee Societal 1 year No 2005 UK £5738 11,530155
Usual care Hip/knee Societal Life 3% 2001 US $205 334189
Acupuncture Sham
acupuncture
Hip/knee Societal 3 months No 2005 Germany 17,845
euros
30,51930
Acetaminophen
þ oxycodone
Oxycodone Hip/knee Societal 4 months No 2006 UA 149/
0.01
More expensive & less
effective190
NSAIDþ PPI NSAIDs OA/RA NHS 6 months No 2005 UK £33,889 64,856191
NSAIDþmisoprostol NSAIDs OA/RA NHS 6 months No 2005 UK £8889 17,011191
Oral ibuprofen Topical
ibuprofen
Knee pain Societal 2 years Yes 2008 UK £27,130 49,44857
Cox-2 speciﬁcs NSAIDs OA/RA NHS 6 months No 2005 UK £36,923 70,663191
Cox-2 selectives NSAIDs OA/RA NHS 6 months No 2005 UK £30,000 57,414191
IAHA Standard care Knee Societal 1 year No 2002 Canada $10,000 13,87679
Total hip replacement Conventional
therapy
Hip Societal Life 5% 1996 US $4754 8964192
Pre-operation Hip Societal Life 5% 2007 Finland 6710
euros
12,024193
TKR Pre-operation Knee Institutional 2 years No 1997 US $5856 11,042194
Unicompartment knee
arthroplasty
Pre-operation Knee Societal Life 5% 2007 Finland 13,995
euros
25,079193
TKR Unicompartment
knee OA
Societal Life 3% 2006 US $250 428140
* Perspective¼ perspective for EE (societal¼ costs and beneﬁts to whole society; NHS¼ costs and beneﬁts to the National Health Service; Institutional¼ costs and beneﬁts
to other payers e.g., insurance company).
y The original cost per QALY was converted into US$ with an inﬂation rate of 5% pa from the date of the study to the current value on 8 May 2009.
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comprehensive SR is the 2006 Cochrane review65. This reviewed
76 trials; including 40 vs placebo, 10 vs IA corticosteroid, six vs
NSAIDs, ﬁve vs physical/exercise therapy, two vs arthroscopy, two
vs conventional therapy and 15 in which different HA products
were used as comparators. A number of different HA products
have been examined, and in most studies they have been
administered at weekly intervals for 3–5 weeks. Treatment effects
were assessed at 1–4 weeks, 5–13 weeks, 14–26 weeks and 45–52
weeks. The pooled ES vs placebo at 1–4 weeks was 0.60 (95% CI
0.37, 0.83) for reduction in pain, 0.61 (0.35, 0.87) for improvement
in physical function and 0.54 (0.17, 1.26) for reduction in stiff-
ness, with an NNT of 7 (3, 119) for the patients’ global assessment
of a positive clinical response (Table I) but an asymmetric funnel
plot and positive Egger test suggested the possibility of publica-
tion bias. There was also very considerable heterogeneity of
outcomes between trials. When analysis is restricted to high
quality studies with a Jadad score of 5, there is no evidence for
signiﬁcant relief of pain (Table III). Inconclusive data from an
earlier MA suggested that the heterogeneity between trials might
be due to the higher molecular weight products having greater
efﬁcacy70. A more recent MA74 of 13 RCTs compared outcomes
following IA injections of high molecular weight Hylan with IA
injections of standard HA products in a total of 2085 patients with
knee OA. The pooled ES showed that IA Hylan was not signiﬁ-
cantly more effective in relieving pain (0.27, 95% CI 0.01, 0.55)
but there was a high degree of heterogeneity between trials with
an I2 of 88%. The pooled ES was close to zero when only trials with
blinded patients, adequate concealment of allocation and ITT
analysis were included. Reduction in pain diminished with time,
and was no longer signiﬁcant after 14 weeks. In 10 trials
comparing IAHA injections with IA corticosteroids there were nosigniﬁcant differences 4 weeks after injection but IAHA was
shown to be more effective 5–13 weeks post injection65.
This is further supported by a recent MA of seven RCTs in
patients with knee OA in which IAHA was compared directly with
IA corticosteroid78. Pain relief was greater following IA corticoste-
roids at 2 weeks (ES¼ 0.39, 95% CI 0.12, 0.65), but not at 4 weeks
(ES¼ 0.01, 95% CI 0.21, 0.23). IAHA was followed by superior
reduction in pain at 8 weeks (ES¼ 0.22, 95% CI 0.5, 0.49) and the
difference in symptomatic beneﬁt favouring IAHA became statis-
tically signiﬁcant at 12 weeks (ES¼ 0.35, 95% CI 0.03, 0.66) and 26
weeks (ES¼ 0.39, 95% CI 0.18, 0.59).
Analyses of the results for other outcomes such as reduction in
stiffness and improvement in function following IAHAwere similar.
No major safety issues were detected, apart from some local
adverse events such as transient pain and swelling at the injection
site (RR¼ 1.49, 95% CI 1.21, 1.83)65. MA for adverse events showed
that IA injections of high molecular weight Hylan were followed by
a greater frequency of ﬂares of pain and swelling compared to the
standard IAHA (RR¼ 2.04, 95% CI 1.18, 3.53)74. The cost per QALY for
IAHA compared with standard therapy was $13,87679 (Table V).
Glucosamine
One SR80 and three new RCTs34,81,82, which examined evidence
for symptomatic efﬁcacy of glucosamine preparations in OA, have
been published since 2006. There are now 20 published placebo-
controlled RCTs of glucosamine in OA, of which 19 provided data for
further analysis, including 16 in which glucosamine sulphate (GS)
preparations (13 oral, two intra-muscular and one IA) have been
used and three in which glucosamine hydrochloride (GH) was
given. Pharmacological effects of GS and GH should not differ as
both dissociate in the acid milieu of the stomach to release an
identical amino sugar, glucosamine83. The calculation of ES for pain
-0.20 0.05 0.30 0.55 0.80 1.05
 After 1998 
 (n=9, pts=1240, I
2
=0%)
0.13 (0.02, 0.25)
Jadad score=5 
 (n=7, pts=1257, I
2
=84%)
0.29 (0.003, 0.57)
Glucosamine hydrochloride  
 (n=3, pts=934, I
2
=0%)
-0.02 (-0.15, 0.11)
Glucosamine sulphate (GS)  
(n=17, pts=1862, I
2
= 87%)
0.58 (0.30, 0.87)
Overall
 (n=20, pts=2769, I
2
=87%)
0.46 (0.23, 0.69)
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Quality of GS trials 
Effect size and 95% confidence interval
Fig. 4. Analgesic efﬁcacy of glucosamine in OA: analysis of RCTs according to formulations employed and quality of trials.
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glucosamine products was based on the 2005 Cochrane review84
where outcomes of RCTs were pooled regardless of the formula-
tions employed (0.61, 95% CI 0.28, 0.95)2. MA of RCTs, including
those published after 2006, in which GS or GH has been given
showsmoderate symptomatic efﬁcacy, ES¼ 0.46 (95% CI 0.23, 0.69)
but there is signiﬁcant heterogeneity of outcomes (I2¼ 87%,
P< 0.0001) as well as considerable evidence of publication bias
(P¼ 0.002 using the Egger test). The ES for pain reduction was 0.58
(95% CI 0.30, 0.87) for GS but insigniﬁcant for GH, ES¼0.02 (95%
CI 0.15, 0.11) (Fig. 4). Whilst the outcomes of trials for GH were
homogenous (I2¼ 0%), those for GS were very heterogeneous
(I2¼ 87%). Egger test analysis of the trials using GS also suggests
signiﬁcant publication bias (P¼ 0.009) but the small number of0 1
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Fig. 5. Cumulative MA of RCTs of aRCTs in which GH has been utilised (n¼ 3) precludes such analysis.
When analysis of trials of GS is limited to high quality RCTs
(Jadad¼ 5) the ES is 0.29 (95% CI 0.003, 0.57) (Fig. 4) and there is no
evidence of publication bias (P¼ 0.74 using the Egger test), but
heterogeneity of outcomes remains considerable (I2¼ 84%,
P< 0.0001). When trials with low quality scores (Jadad score< 5)
and the one trial with exceptionally large effect (ES¼ 1.27, 95% CI
0.89, 1.58), are excluded, outcomes of trials with GS become
homogeneous (I2¼ 0%) but efﬁcacy is greatly reduced (ES¼ 0.15,
95% CI 0.03, 0.27) (Table III). CumulativeMA of RCTs of GS from 1981
to 2008 shows a progressive diminution of ES (Fig. 5). Further
analysis of the data included in the SR of 15 RCTs published in
200780 shows homogeneity (I2¼ 9%) but no efﬁcacy in trials in
which allocation concealment was adequate; ES¼ 0.04 (95% CI2 3 4
0.58 (0.30, 0.87)
0.64 (0.33, 0.94)
0.68 (0.34, 1.03)
0.75 (0.39, 1.12)
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nalgesic efﬁcacy of GS in OA.
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Fig. 6. Funnel plot of trials of analgesic efﬁcacy of CS in OA.
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with an ES¼ 0.42 (95% CI 0.19, 0.64) in trials with inadequate
allocation concealment. Efﬁcacy in RCTs using ITT analyses was less
than in those that did not: ES¼ 0.23 (95% CI 0.002, 0.46) vs
ES¼ 0.53 (95% CI 0.06, 1.00); and was absent in investigator led
RCTs that were not industry funded ES¼0.002 (95% CI0.11, 0.11)
compared with an ES¼ 0.44 (95% CI 0.18, 0.71) in the industry
funded studies.
While the three trials utilising GH were undertaken after
publication of the consolidated standards for reporting clinical trial
(CONSORT) statement85, a number of the trials in which GS was
used were published before the adoption of consolidated standards
for the reporting of clinical trials by the majority of journals in
199885. When analysis is restricted to all RCTs of GS published since
1998 the outcomes are homogenous (I2¼ 0%) and there is no
evidence of publication bias (P¼ 0.76 using the Egger test) but
efﬁcacy is diminished; ES¼ 0.13 (95% CI 0.02, 0.25) (Fig. 4).
Evidence for glucosamine products having a possible structure-
modifying effect in patients with knee or hip OA remains
controversial. Three RCTs of GS 1500 mg daily (two in knee OA and
one in hip OA) have been published82,86,87. The pooled ES for
slowing of joint space loss in the medial compartment of the knee
in the two trials in patients with knee OA, which included 414
patients, was small but signiﬁcant (ES¼ 0.24 95% CI 0.04, 0.43).
However, no signiﬁcant decrease in joint space narrowing was
demonstrable in an RCT involving 221 patients with hip OA after
24 months therapy, either in the whole group (ES¼ 0.03 95% CI
0.06, 0.12)82, or in sub-groups pre-deﬁned for severity and
whether the OA was localised or generalised88. There was also no
evidence of signiﬁcant reduction of joint space narrowing of the
medial compartment of the knee over 24 months in a sub-group of
77 patients with knee OA treated with GH 1500 mg/day in the
Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
(ES¼ 0.15, 95% CI 0.07, 0.38)89.
A follow-up observational study of the patients with knee OA
that had participated in the RCT of GS showed that the 5-year
incidence of total knee replacement (TKR) in patients who had
taken GS 1500 mg/day for at least 12 months was less than half of
that in those who had taken placebo (6.3 vs 14.5%) (P¼ 0.0024)90.
The use of joint replacement surgery as a reliable end point for
trials of structure-modifying therapies in OA is, however, not yet
established91. The decision to undertake joint replacement surgery
is inﬂuenced by many factors; such as the severity of pain and
disability, the patients age, gender92 and co-morbidities, as well as
the surgeon’s threshold for recommending the procedure and the
patient’s willingness to undergo surgery.
Chondroitin sulphate (CS)
Five MA have been undertaken44,93–96. The most recent 2007
MA of 20 trials involving 3846 patients95 demonstrated pain relief
with a moderate to large ES (ES¼ 0.75, 95% CI 0.50, 0.99). However,
there was evidence of publication bias in favour of trials of CS
having positive outcomes (Fig. 6), and the results were extremely
heterogeneous (Fig. 7) (I2¼ 92%). Cumulative MA demonstrates
a chronological reduction in the ES (Fig. 8). When the analysis is
restricted to high quality trials with a Jadad score of 5, there is no
evidence for signiﬁcant relief of pain (ES¼ 0.005, 95% CI0.11, 0.12)
(I2¼ 0%) (Table III).
Trials which examined whether CS might have structure-
modifying effects were systematically reviewed in 200897. Four
company-sponsored RCTs in patients with knee OA (three full
reports and one abstract) were included in this review. There was
no heterogeneity in outcomes between trials and the pooled results
demonstrated a small but signiﬁcant reduction in the rate of
decline of joint space narrowing per year in patients treatedwith CScomparedwith placebo (ES¼ 0.26, 95% CI 0.16, 0.36). More recently,
the full report of one of these trials was published98. Loss of
minimum joint space width (JSW) over 2 years was signiﬁcantly
lower in the treated patients (0.07, S.E.M. 0.03) than in those
treated with placebo (0.031, S.E.M. 0.04) (P< 0.0001)98.
Avocado soybean unsponiﬁables (ASU)
Evidence for symptomatic efﬁcacy of ASU (300 mg/day for 3–12
months) was assessed in a recent SR of four industry-sponsored
RCTs involving 272 patients with hip OA and 392 patients with OA
knee99. The overall ES for pain reductionwas 0.39 (95% CI 0.01, 0.76)
but there was considerable heterogeneity of outcomes (I2¼ 83%).
The ES was smaller (0.22, 95% CI 0.06, 0.51) and heterogeneity
was reduced (I2¼ 61%) when analysis was limited to high quality
trials (Jadad score¼ 5) (Table III). Treatment with ASU was also
associated with moderate improvement in the Lequesne index
(ES¼ 0.45, 95% CI 0.21, 0.70; I2¼ 61%). Twice as many patients
responded to ASU when compared with placebo (RR¼ 2.19,
P¼ 0.007) with an NNT of 6 (95% CI 4, 21).
Vitamin E
As part of a wider SR of the efﬁcacy of antioxidant vitamins and
selenium in patients with inﬂammatory joint diseases and OA, six
RCTs of vitamin E in patients with OA (four vs placebo, two vs
diclofenac) were systematically reviewed100. The studies were poor
in quality and the results were equivocal. Vitamin E gave better
relief of pain than placebo in two small, short-term, studies but was
no better than placebo in two larger, longer-term, placebo-
controlled RCTs and appeared to give equivalent pain relief to
diclofenac in two active control trials. Further high quality trials are
needed.
Other nutritional supplements
SRs of trials of the nutritional supplements Perna Canaliculus
(green-lipped mussel)101, dimethyl sulfoxide (DMSO) and meth-
ylsufonylmethane (MSM)102,103 for the treatment of OA concluded
that deﬁnitive evidence for efﬁcacy of green-lipped mussel
extracts, DMSO and MSM, was not established because of meth-
odological ﬂaws in the RCTs. The RCTs of MSM in >150 patients
with knee OA were, however, more rigorous. In one12-week
double blind placebo-controlled trial MSM 500 mg tid resulted
in signiﬁcant improvement in a Likert pain scale and in the
Lequesne functional index104 and in another 12-week double
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Conrozier 1998 0.57 (0.18, 0.96)
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Fig. 7. Forest plot of trials of analgesic efﬁcacy of CS in OA.
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superior to placebo in decreasing WOMAC pain and functional
scores105.
S-Adenosylmethionine (SAM-e) is widely used as a dietary
supplement by patients with OA in the USA, despite a 2002 SR
which suggested that SAM-e had no signiﬁcant efﬁcacy in relief of
pain in knee OA (ES¼ 0.22, 95% CI 0.25, 0.69)106, No new RCTs or
SRs of SAM-e in the treatment of hip or knee OA were published
between 2006 and 2009 but a single double blind cross-over RCT
comparing SAM-e (600 mg bd) with celecoxib (100 mg bd) in 61
patients with knee OA showed that while celecoxib gave better
relief of pain after 1 month (P¼ 0.024) there was no signiﬁcant
difference in pain relief between the treatment groups at 2
months107.
Other herbal remedies
Herbal medicines are very widely used by patients with symp-
tomatic hip and knee OA. In addition to the evidence for efﬁcacy of
ASU reviewed above there are now >15 SRs of variable quality of
trials of rosehip powder, devil’s claw (Harpagophytum procumbens),
ginger, willow bark extracts, Salai guggal and a number of other
herbal preparations. A recent MA of three manufacturer-supported
placebo-controlled RCTs of a rosehip powder from Rosa canina (the
Dog Rose) in 287 patients with OA in various joints found thatrosehip powder had a small but signiﬁcant effect in reducing pain
(ES¼ 0.37, 95% CI 0.13, 0.60)108. Outcome was homogeneous
between trials (I2¼ 0%) and patients receiving rosehip powder
responded twice as frequently as those on placebo (OR 2.19) cor-
responding to a NNTof 6 (95% CI 4, 13)108. A 2006 review of 14 trials
of H. procumbens in patients with OA included four double blind
placebo-controlled RCTs109. The better quality placebo-controlled
trials with >50 mg harpagoside daily demonstrated some efﬁcacy
for relief of pain101 but evidence for pain relief with ginger, Bos-
wellia serrata gum resin, willow bark extract and other herbal
preparations is sparse and inconclusive110.
Diacerhein
Diacerhein is an anthraquinone derivative which has been
shown to inhibit IL-1b in in vitro studies111 and to have some slow-
acting, and persisting, symptomatic efﬁcacy in patients with OA of
the knee112–114 and hip115. The SR of the research evidence for
symptomatic efﬁcacy in patients with hip and knee OA from 2002
to 2006was based on four RCTs112,114–116. Efﬁcacy for pain reduction
was small (ES¼ 0.22, 95% CI 0.01, 0.42)2 with considerable
heterogeneity between trials, and diarrhoea was a signiﬁcant
problem (RR¼ 3.98, 95% CI 2.90, 5.47)2. TwoMAswere published in
2006117,118 and one further NSAID-controlled RCT was published in
2007116. The updated ES for relief of pain, based on analysis of six
0 1 2 3
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Fig. 8. Cumulative MA of trials of analgesic efﬁcacy of CS in OA.
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diarrhoea compared to placebo is 3.51 (2.55, 4.83) (Table IV).
Anti-resorptive bone-acting agents
Interest in the possibility that drugswhich inhibit bone turnover
might have potential as structure-modifying agents for the treat-
ment of OA followed the demonstration of chondroprotection in
animal models of OA after administration of alendronate, calcitonin
or oestrogen121,122. Treatment with oestrogens and alendronate
have also been associated with signiﬁcantly less knee OA-related
subchondral bone attrition and bone marrow oedema – like
lesions in cohorts of elderly women, than in women not taking
bone anti-resorptive drugs123, but RCTs of agents that suppress
bone turnover have failed to demonstrate slowing of structural
progression in patients with knee OA124. Treatment with risedro-
nate 5 mg/day, 15 mg/day, 35 mg/week or 50 mg/week was not
associated with symptomatic beneﬁt or slowing of radiographic
progression as measured by decreased JSW over 2 years in a large,
multinational, placebo-controlled RCT involving 2483 patients with
medial compartment knee OA in Europe and North America124,
despite dose-dependent reduction in urinary levels of the
C-terminal cross-linking telopeptide of type II collagen (CTX-II),
a cartilage degradation biomarker that has been shown to be
associated with progression of knee OA125. Comparable reduction
in CTX-II followed treatment with strontium ranelate126, oestrogen
replacement therapy127, and treatment with the selective oes-
trogen-receptor modulator (SERM) levomeloxifene128. Levels of
CTX-II, type II collagen neoepitope (C2C) and matrix metal-
loproteinase 13 (MMP 13) were also signiﬁcantly reduced following
administration of oral salmon calcitonin 1 mg/day for 84 days in
a preliminary, and much smaller, placebo-controlled RCT in 41patients with knee OA, and this appeared to be associated with
statistically signiﬁcant improvement in the Lequesne algofunc-
tional index129.
Surgical treatments
Lavage/debridement
Three RCTs have been published130–132 following Moseley’s
landmark study133 in which 180 patients with knee OA, randomly
assigned to arthroscopic debridement, arthroscopic lavage or
placebo (sham) surgery with a skin incision and simulated
arthroscopy, showed no signiﬁcant differences between the groups
in the primary end point (pain on a self-reported 12-item knee
speciﬁc pain score), or any of the other secondary outcome
measures of pain or function133. To date there are no SRs of joint
lavage as a treatment for OA knee but a Cochrane review of
arthroscopic debridement for knee OA was published in 2008134.
This concluded that there was ‘gold’ level evidence (www.
cochranemsk.org) that arthroscopic debridement provided no
beneﬁt in patients with unselected OA knee (LoE Ib). Seven placebo
(sham) or active (e.g., lavage plus exercise vs exercise alone)
controlled RCTs have been reported. All included relatively long-
term observations ranging from 3 months to 2 years. To allow
some comparability with other treatments, the 3-month observa-
tion point has been used to estimate the efﬁcacy of this therapy.
Investigators employed either closed needle lavage130,135 or
arthroscopic lavage131,132 but only Moseley’s study133 clearly
separated lavage from debridement. The pooled results showed no
beneﬁt for lavage and/or debridement over placebowith ESs of 0.21
(95% CI 0.12, 0.54) for pain relief, 0.11 (0.11, 0.33) for improve-
ment in function and 0.05 (0.34, 0.44) for reduction in stiffness
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high quality trials (Table III). However, one recent single blind RCT
compared tidal irrigation (n¼ 71) with IA corticosteroid injections
(n¼ 79). Both treatments were equally effective at 4 weeks and the
tidal irrigation was superior to IA steroid injection after 26
weeks136.
Other surgical therapies
A Cochrane SR of the efﬁcacy and safety of correction osteotomy
for the treatment of unicompartment knee OA was updated in
2007137. Thirteen studies involving nearly 700 patients were
reviewed. All concerned high tibial osteotomy (HTO) for medial
compartment knee OA. Six studies compared two techniques of
HTO, four studies compared different perioperative or post-oper-
ative care and one study compared HTO alone with HTO plus
additional treatment. However, no studies have been undertaken to
compare HTO with placebo (sham) surgery or conservative treat-
ment alone. Two studies including one with 5 years follow-up
compared HTO with unicompartmental joint replacement. The
heterogeneity of studies precluded pooling of outcomes but the
authors concluded that despite lack of comparisons with placebo or
non-operative treatments there was ‘silver’ level evidence (www.
cochranemsk.org) that valgus HTO does have some efﬁcacy in
reducing pain and improving function (LoE IIa). An earlier MA
published in 2004 found that the overall failure rate for HTO at 10
years was 25% and the average time between HTO and joint
replacement surgery was 6 years138.
Another SR published in 2007, compared the safety and efﬁcacy
of unicompartmental knee arthroplasty (UKA) in patients with
knee OA, with HTO and total knee arthroplasty (TKA)139. Three
RCTs, two controlled trials and three cohort studies were reviewed
for function (primary efﬁcacy outcome), post-operative pain,
complications and revision rate. Similar percentages of patients had
improvement in function following UKA and TKA (RR¼ 1.03, 95% CI
0.97, 1.10) and HTO (1.26, 95% CI 0.95, 1.19), but fewer patients
experienced complications such as deep vein thrombosis following
UKA (RR¼ 0.34, 95% CI 0.14, 0.81), and the revision rate was lower
following UKA than HTO (RR¼ 0.51, 95% CI 0.29, 0.89)139. When
compared with TKA, the cost per QALY for UKA was only $428140.
Discussion
The OARSI evidence-based, expert consensus recommendations
for the treatment of OA of the hip and knee were published in
20081 following critical appraisal of existing guidelines and an SR of
the evidence for relevant therapies from 2002 until January 20062.
This paper updates the published evidence for available therapies
from 31 January 2006 to 31 January 2009, as an aid to determining
whether any of the current treatment recommendations1 require
modiﬁcation at this time.
Timing of updates of evidence and recommendations
The value of clinical practice guidelines is diminished if the
scientiﬁc evidence on which they are based is out of date141,142 and
the National Guideline Clearinghouse (www.guideline.gov) data-
base is limited to guidelines that have been developed, reviewed or
revised within the last 5 years. Reassessment of guidelines for
validity every 3 years was recommended in 2001 after it was
demonstrated that three quarters of guidelines published by the US
Agency for Healthcare Research and Quality (AHRQ) were in need
of updating142. However, setting arbitrary dates for the SR of new
evidence and for revision of recommendations may not be appro-
priate. While some treatment guidelines, in rapidly evolving ﬁelds,
become outdated very quickly, early revision of recommendationscan be both wasteful of time and resources, and unnecessarily
confusing for clinicians, in more slowly evolving areas of medicine.
There are currently no generally accepted criteria for determining
what kind of new evidence should trigger the need to modify
existing treatment guidelines143, or when SRs should be upda-
ted144. It has been suggested that there are six situations which
should trigger an update of clinical practice guidelines143:
1. Changes in evidence of existing beneﬁts and harms of available
therapies.
2. Changes in outcomes considered to be important.
3. Changes in available treatments.
4. Changes in evidence that current treatment practice is optimal.
5. Changes in social or economic values that individuals or society
place on particular outcomes
6. Changes in resources available for health care.
To these one might add:
7. Changes to correct errors identiﬁed following publication,
feedback and independent review145.
This paper provides a systematic update of evidence for the
beneﬁts and harms of new and existing therapeutic options for the
treatment of hip and knee OA published between 31 January 2006
and 31 January 2009. It also examines the potential inﬂuence of this
new evidence, by placing it in the context of all the available
scientiﬁc literature, using sensitivity analyses and cumulative MAs.
Methodology
The search strategies, electronic databases and criteria for
inclusion and exclusion of studies were identical to those previ-
ously employed and only cost-utility analyses were included for
determination of cost-effectiveness2. For each CUA, the study
perspective, comparator, time horizon, discounting, modelling and
uncertainty were evaluated. We selected the best available
evidence, both in the 2006 SR2, and in the current systematic
update of evidence primarily based on the evidence hierarchy5. The
quality of individual SRs/MAs has been assessed using the Oxman
and Guyatt checklist3 and the quality of RCTs evaluated using the
Jadad method4. The Jadad4, or Oxford quality scoring system, is the
best validated and most widely used of more than 20 scales146 that
have been employed to assess the quality of RCTs. It is simple to use
and focuses on the assessment of three important components that
contribute to the internal validity of RCTs; randomisation, blinding
and withdrawals. It can be criticised, however, for being too
simplistic147, for placing too much emphasis on the quality of
reporting of trials and not enough on the quality of the methods,
and for not including assessments of allocation concealment or ITT
analysis148, both of which can be important sources of bias in RCTs.
As analysis of individual components of trial quality can provide
information that is not captured in a composite score of trial
quality, original studies included in the SRs/MAs were assessed for
quality characteristics; including allocation concealment, the
distribution of ES, evidence of heterogeneity and the likelihood of
publication bias, wherever possible. Sensitivity analyses were used
to examine changes in evidence between 2006 and 2009 and
changes inﬂuenced by the quality of the studies.
Cumulative MAs
Cumulative MAwas used to assess changes in treatment ES year
by year, in order to detect any signiﬁcant trends associated with
accruing evidence. The value and potential hazards of this tech-
nique are well illustrated in the cumulative MA of the ES for pain
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(Fig. 3) and RCTs of GS (Fig. 5) and CS published between 1992 and
2008 (Fig. 8). In the former case the ES for acetaminophen, though
very small, had apparently stabilised and remained statistically
signiﬁcant in the context of an absence of evidence of publication
bias, suggesting that further RCTs to test analgesic efﬁcacy were not
required. It should be noted, however, that acetaminophen had no
signiﬁcant efﬁcacy for relief of pain when only high quality trials
were considered (ES¼ 0.10, 95% CI 0.00, 0.23). In the latter cases
cumulative MAs show an impressive chronological reduction in the
ES for pain relief in RCTs of GS and CS (Figs. 5 and 8), suggesting an
instability of efﬁcacy, which may be attributable, at least in part, to
an increase in the quality of studies after the CONSORT statement
was published and widely adopted as a standard for conducting
RCTs in 199885. When the analyses are restricted to high quality
trials with Jadad scores of 5, GS appears to have modest symp-
tomatic efﬁcacy (ES¼ 0.29, 95% CI 0.003, 0.57) but CS does not
(ES¼ 0.005, 95% CI 0.11, 0.12) (I2¼ 0%) (Table III). However, funnel
plots demonstrate signiﬁcant asymmetric distribution for CS
(Fig. 6) and GS (data not shown) suggesting signiﬁcant publication
bias. As positive trials and trials with larger ES are more likely to
have been published, it is very probable that the ES will become
smaller in the future following publication of further RCTs if
publication bias is eliminated.
CumulativeMA can also be used retrospectively to identifywhen
a treatment ES ﬁrst reached levels that were statistically signiﬁcant,
or when signiﬁcant adverse effects ﬁrst became apparent149.
Although cumulativeMAcanprovide important evidence to suggest
that further trials are unnecessary or even unethical150, great care
must be taken to ﬁrst ensure that potential biases in the RCTs being
subjected to MA are sought for and excluded6,150.
Strengths and limitations
An independent narrative review of the OARSI treatment guide-
lines151 drew attention to some dilemmas such as how to weigh
conclusions from a ﬂawed MA against the results from a more recent
highqualityRCT, the resultsofwhichhadnotbeen included in themost
recent MA; or what should be done about pooled ES estimates from
high qualityMAs, the authors ofwhich had themselves questioned the
results because of concerns aboutmethodological ﬂaws in some of the
included RCTs. McAlindon also focussed attention on the general
dilemma of how best to deal with data from SRs and RCTs published
after the closing date of the SRof evidence151. In so doing, he threwout
a challenge to the OARSI Treatment Guidelines Committee to consider
the possibility of exploring alternative methods for guideline devel-
opment that could facilitate frequent updates, or even real time
adjustments to recommendations in a fast moving ﬁeld.
Many evidence-based treatment guidelines, including the OARSI
recommendations for the management of hip and knee OA1 have
used the ‘best available evidence’, according to a widely accepted
evidence hierarchy5, to guide recommendations. While this has the
important advantage that the guideline developers are spared the
need to undertake an SR for every treatment modality, it has
a number of limitations:
 SRs/MAs may not provide better evidence than individual RCTs
in certain instances.
 The results of some important high quality RCTs may have
become available after the publication of the latest SR/MA.
 It may be difﬁcult to determine which RCT provides the best
evidence for efﬁcacy of a modality of treatment when no SR/
MA is available.
 Evidence for certain treatment modalities (e.g., surgical ther-
apies) is often based on uncontrolled observational studies andcohort studies where outcomes have been compared with
standard medical care or historical controls. Whereas in the
past RCTs were thought to be precluded for surgical treatments
for ethical and methodological reasons, recent studies have
emphasised that it is both necessary and possible to undertake
RCTs of surgery in musculoskeletal diseases130–133,152,153.
Most importantly:
 It is not always easy to determine which SR/MA provides the
best available evidence when several have been undertaken.
 Cross-treatment comparisons may not be possible when SRs/
MAs have used differing inclusion/exclusion criteria for RCTs.
For example anMA of all trials for GS showed signiﬁcant efﬁcacy
for pain relief with a moderate ES (ES¼ 0.61, 95% CI 0.28, 0.95),
whereas in a sub-group analysis of trials judged to have adequate
allocation concealment efﬁcacy was not apparent (ES¼ 0.04, 95% CI
0.09, 0.17)84. Although there are cogent arguments for using
either approach, the OARSI Treatment Guideline Committee fav-
oured pooling of all available trial data for each modality of therapy
in order to facilitate comparisons of ES across treatments based on
the published MAs. Further comparisons should be made using the
same criteria, rather than applying different quality criteria for
inclusion of trials in the MAs for different modalities of therapy.
As the publication of new RCTs and SRs/MAs increases
progressively it would be very useful to have available a continu-
ously updated, comprehensive, and coherent database of well-
characterised trials of all modalities of treatment of OA. Such
a database would:
 Allow statistical pooling of data at any time point for a variety
of analyses based on different inclusion/exclusion criteria.
 Provide an unconstrained hypothesis-free database of OA
therapy that can be used to generate and test new hypotheses.
 Assist clinical decision making for all treatments under
consideration.
However, care must be taken to continue to distinguish the
processes that lead to formulating treatment guidelines and the
strength of expert consensus recommendations, which are based
on expert assessment of the ‘best evidence’ available; from the
updated cumulative evidence itself. Following appraisal of the
cumulative, updated evidence contained in this paper, and any
feedback from stakeholders that may follow publication, the OARSI
Treatment Guideline Committee will review the current OARSI
recommendations1 and reach consensus on whether changes
should be made in 2010.
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Appendix I. Glossary of terms and abbreviations
(in alphabetic order)
AAOS: American Academy of Orthopaedic Surgeons.
AHRQ: Agency for Healthcare Research and Quality.
ASU: avocado soybean unsponiﬁables.
CI: conﬁdence interval.
CONSORT: consolidated standards for reporting clinical trials.
Cost-effectiveness analysis (CEA): a form of economic evaluation
in which the costs and consequences of alternative interven-
tions are expressed as cost per unit of health outcome as
measured in physical or natural units. Natural units could range
from clinical measures, such as pain reduction, through total
joint replacement saved and life-years gained. It is also used as
a general term for economic evaluation in the US.
Cost-utility analysis (CUA): a form of economic evaluation inwhich
the costs and consequences of alternative interventions are
expressedas costperquality-adjusted lifeyear (QALY) gained.QALY
combines changes in quantity and quality of life (QoL) into one
compositemeasurewhich is independentofprogrammeordisease.
It, therefore, allows cross-programme/disease comparisons and is
an outcome very useful for policy making and resource allocation.
Cox-2: cyclooxygenase-2.
CS: chondroitin sulphate.CTX-II: C-terminal cross-linking telopeptide of type II collagen.
Cumulative meta-analysis: repeated performance of meta-
analysis whenever a new trial becomes available for inclusion.
DMSO: dimethyl sulfoxide.
EE: economic evaluation (UK) or cost-effectiveness analysis
(US). These are studies which measure both the clinical
effectiveness (e.g., pain reduction) and the costs (resource)
incurred in achieving the clinical outcome and the treatment
of any adverse consequences of the treatment. The incremental
cost-effectiveness ratio (ICER) is a way of presenting this
composite measure. It is calculated by dividing the difference
in costs by the difference in effectiveness of alternative
therapies.
Egger test: a regression test used in conjunction with Funnel
plots to detect publication bias in meta-analyses.
ES: effect size. This is a standard mean difference between
groups (e.g., treatment vs placebo). ES is calculated by dividing
the mean difference between treatments by the standard
deviation of the difference. It is, therefore, a number without
units that can be used for cross-study comparisons. Clinically
ES¼ 0.2 is considered small, ES¼ 0.5 is moderate and ES> 0.8 is
a large effect.
EULAR: European League Against Rheumatism.
FDA: Federal Drug Administration.
Funnel plot: a funnel plot is a scatterplot of treatment effect
against a measure of study size or sampling error. It is used
primarily as a visual aid to detect bias or systematic hetero-
geneity. An asymmetric funnel suggests the possibility of
either publication bias or a systematic difference between
smaller and larger studies. Whatever the cause, an asym-
metric funnel plot suggests that simple statistical pooling is
inappropriate.
GAIT: Glucosamine/Chondroitin Arthritis Intervention Trial.
GFR: glomerular ﬁltration rate.
GH: glucosamine hydrochloride.
GI: gastrointestinal.
Gold and Silver evidence: Cochrane collaboration musculoskel-
etal group gradings for levels of evidence. ‘Gold’ level – one RCT;
‘Silver’ level – either one randomised trial with head to head
comparisons or high quality case–control study.
GS: glucosamine sulphate.
GUIDE: Glucosamine Unum in Die (once a day) Efﬁcacy trial.
H2 blocker: histamine H2 receptor antagonist.
HR: hazard ratio is a relative riskmeasure for time-to-event data. It
is speciﬁcally useful for survival analysis, where HR gives an esti-
mateof theoveralldifferencebetween thesurvival curves. If there is
no difference between two groups the value of the HR¼ 1.
HTO: high tibial osteotomy.
I2: is the degree of heterogeneity in outcomes between studies
expressed as a percentage. It is a measure of the variation in
outcomes across studies that is not due to chance.
IAHA: intra-articular hyaluronic acid.
ITT: intention to treat analysis.
JSW: joint space width.
LoE: level of evidence. This is based on an evidence hierarchy in
which studies are ranked according to the quality characteristics
of the study design, or information available. In this hierarchy
systematic review/meta-analysis of randomised controlled
trials (RCTs) are regarded as providing the highest LoE (Ia) for
efﬁcacy; followed by a single RCT (Ib), non-RCT (IIa), quasi-
experimental study (IIb), comparative observational study (III),
and expert opinion (IV).
MA: meta-analysis is a systematic review of research evidence
that includes a statistical analysis which examines the
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MMP: matrix metalloproteinase.
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NA: not available.
NICE: National Institute of Health and Clinical Excellence.
NNT: number needed to treat. This is the number of patients that
would need to be treated to achieve a target treatment effect.
The smaller the NNT, the better the therapy; the greater the
NNT, the less effective is the treatment.
NNH: number needed to harm. This is the number of patients
that would need to be treated to have an unwanted effect. The
smaller the NNH, the more risk is the treatment; the greater
NNH, the less risk is the treatment.
NSAID: non-steroidal anti-inﬂammatory drug.
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OARSI: Osteoarthritis Research Society International.
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Publication bias: publication bias is a type of selection bias when
publishing research results. For example, studies with positive
ﬁndings are more likely to be published, and outcome measures
with positive results are more likely to be reported.
QALY: quality-adjusted life year is a measure of health that
encompasses both the quality and the quantity of life. It is used
to compare the overall value of different treatments. It is
measured by calculating the number of years of life gained as
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